AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7698688 — intervention group
Group type: COMPARATOR
Intervention: No test meal
Number of subjects: 7
Study 2678230 — intervention group
Group type: EXPERIMENTAL
Intervention: Amidotrizoate
Number of subjects: 16
Study 2678230 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 16
Study 53111 — intervention group
Group type: EXPERIMENTAL
Intervention: 35S-methimazole (MMI)
Number of subjects: 55
Study 53111 — intervention group
Group type: EXPERIMENTAL
Intervention: 35S-propylthiouracil (PTU)
Number of subjects: 55
Study 53111 — intervention group
Group type: EXPERIMENTAL
Intervention: 35S-carbimazole
Number of subjects: 55
Study 30932797 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Quality Index-International (DQI-I) scores
Number of subjects: 1300
Study 30932797 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender and maternal education levels
Number of subjects: 1300
Study 28039505 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling added to a printed survivorship care plan
Number of subjects: 411
Study 28039505 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention
Number of subjects: 411
Study 28039505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic motivation
Number of subjects: 411
Study 28039505 — intervention group
Group type: EXPERIMENTAL
Intervention: Competency
Number of subjects: 411
Study 28039505 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional control
Number of subjects: 411
Study 26320930 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying a place for care
Number of subjects: 185
Study 26320930 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a medical condition
Number of subjects: 185
Study 26320930 — intervention group
Group type: EXPERIMENTAL
Intervention: Having depression
Number of subjects: 185
Study 26320930 — intervention group
Group type: COMPARATOR
Intervention: Not being involved in care decisions
Number of subjects: 185
Study 22674191 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 28
Study 22674191 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 28
Study 22674191 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 28
Study 22674191 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin and Bicalutamide
Number of subjects: 28
Study 22674191 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine treatment
Number of subjects: 28
Study 21476025 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA participants
Number of subjects: 788
Study 21476025 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 788
Study 18642207 — intervention group
Group type: EXPERIMENTAL
Intervention: DALK
Number of subjects: 732
Study 18642207 — intervention group
Group type: COMPARATOR
Intervention: PKP
Number of subjects: 732
Study 16517325 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (30 microg kg(‐1)) and thiopentone
Number of subjects: 104
Study 16517325 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1.5 microg kg(‐1)) and thiopentone
Number of subjects: 104
Study 12652055 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly folic acid supplement (2,800 microg)
Number of subjects: 138
Study 12652055 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily folic acid supplement (400 microg)
Number of subjects: 138
Study 12652055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 11101478 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose 12 g plus 50 g glucose
Number of subjects: 0
Study 11101478 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose intake
Number of subjects: 0
Study 8610862 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg metoclopramide
Number of subjects: 60
Study 8610862 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study 1306643 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise breast milk
Number of subjects: 26
Study 1306643 — intervention group
Group type: COMPARATOR
Intervention: Pre-exercise breast milk
Number of subjects: 26
Study 6096982 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcuticular absorbable (Dexon) suture
Number of subjects: 113
Study 6096982 — intervention group
Group type: COMPARATOR
Intervention: Metal skin staples (Autosuture)
Number of subjects: 113
Study 6096982 — intervention group
Group type: COMPARATOR
Intervention: Nylon vertical mattress suture
Number of subjects: 113
Study 6096982 — intervention group
Group type: COMPARATOR
Intervention: Adhesive sutureless skin closure (Op‐site)
Number of subjects: 113
Study 6096982 — intervention group
Group type: COMPARATOR
Intervention: Overall incidence of wound infection
Number of subjects: 113
Study 31331572 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillea wilhelmsii capsules, twice daily for 4 weeks
Number of subjects: 49
Study 31331572 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 4 weeks
Number of subjects: 49
Study 31331572 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillea wilhelmsii capsules
Number of subjects: 49
Study 31331572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 28434633 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone propionate 1% ointment twice a day for 30 days
Number of subjects: 35
Study 25883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (group M, n = 30)
Number of subjects: 60
Study 25883103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C, n = 30)
Number of subjects: 60
Study 24922664 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF1R mRNA positive tumors
Number of subjects: 33
Study 24922664 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF1R protein expression
Number of subjects: 33
Study 22932399 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C
Number of subjects: 38
Study 22932399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 20634190 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 500 mg/kg
Number of subjects: 82
Study 20634190 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 82
Study 17198918 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg
Number of subjects: 187
Study 17198918 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 187
Study 16651204 — intervention group
Group type: EXPERIMENTAL
Intervention: Testim 1% (5 g)
Number of subjects: 151
Study 16651204 — intervention group
Group type: COMPARATOR
Intervention: AndroGel 1% (5 g)
Number of subjects: 151
Study 12809386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral men's group
Number of subjects: 268
Study 12809386 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple's group
Number of subjects: 268
Study 12809386 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety and stabilization group
Number of subjects: 268
Study 12809386 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study 9440386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligopeptide-based complete formula (OPD)
Number of subjects: 0
Study 9440386 — intervention group
Group type: COMPARATOR
Intervention: Whole-protein-based complete formula (WPD)
Number of subjects: 0
Study 8541168 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide or flecainide treatment
Number of subjects: 260
Study 8541168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 2235229 — intervention group
Group type: EXPERIMENTAL
Intervention: Group classes discussing myths, problems, and benefits of breast-feeding
Number of subjects: 159
Study 2235229 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual prenatal counseling with a pediatrician or nurse practitioner
Number of subjects: 159
Study 2235229 — intervention group
Group type: COMPARATOR
Intervention: Control group with no additional prenatal education
Number of subjects: 159
Study 2235229 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study 2235229 — intervention group
Group type: EXPERIMENTAL
Intervention: Group classes
Number of subjects: 159
Study 2235229 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual sessions
Number of subjects: 159
Study 637281 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.75%
Number of subjects: 147
Study 637281 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.5%
Number of subjects: 147
Study 637281 — intervention group
Group type: COMPARATOR
Intervention: mepivacaine 1.5% with adrenaline
Number of subjects: 147
Study 31101184 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2)
Number of subjects: 0
Study 28175316 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm including AMH, AFC, age and BMI
Number of subjects: 308
Study 28175316 — intervention group
Group type: COMPARATOR
Intervention: Algorithm including only AFC, age and BMI (Control)
Number of subjects: 308
Study 25533774 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg per day)
Number of subjects: 133
Study 25533774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 25533774 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 133
Study 23164311 — intervention group
Group type: EXPERIMENTAL
Intervention: Early developmental intervention (EDI)
Number of subjects: 0
Study 23164311 — intervention group
Group type: COMPARATOR
Intervention: Control (no early developmental intervention)
Number of subjects: 0
Study 21327351 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial‐numerical training program using full‐body spatial movement on a digital dance mat
Number of subjects: 0
Study 21327351 — intervention group
Group type: COMPARATOR
Intervention: Non‐spatial control training
Number of subjects: 0
Study 19308816 — intervention group
Group type: EXPERIMENTAL
Intervention: High peak reaction force of 123 N (peak torque=8 Nm, build-up time=250 ms)
Number of subjects: 24
Study 19308816 — intervention group
Group type: COMPARATOR
Intervention: Low peak reaction force of 5 N (peak torque=2 Nm, build-up time=50 ms)
Number of subjects: 24
Study 19308816 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 17053058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser therapy (LPLT)
Number of subjects: 38
Study 17053058 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LPLT)
Number of subjects: 38
Study 16170158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEXA) 8 mg/m2 during induction and DEXA 6 mg/m2 during the intensifications
Number of subjects: 359
Study 16170158 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (PRED) 60 mg/m2 during induction and PRED 40 mg/m2 during four intensifications in the SR group and three intensifications in the IR group
Number of subjects: 359
Study 11991446 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 80 mg
Number of subjects: 81
Study 11991446 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 160 mg
Number of subjects: 81
Study 11991446 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (both dosages)
Number of subjects: 81
Study 9473831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg preoperative dose
Number of subjects: 20
Study 9473831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 20
Study 7630676 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol
Number of subjects: 116
Study 7630676 — intervention group
Group type: COMPARATOR
Intervention: Magnesium citrate
Number of subjects: 116
Study 7630676 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 116
Study 7630676 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 116
Study 2550634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 25
Study 2550634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 354746 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (single dose, intravenous infusion)
Number of subjects: 95
Study 354746 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 95
Study 31183442 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS)
Number of subjects: 220
Study 31183442 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 220
Study 29273261 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at 95 mg/m2 for ∗1∗1 genotype
Number of subjects: 26
Study 29273261 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at 80 mg/m2 for ∗1∗28 genotype
Number of subjects: 26
Study 29273261 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at 80 mg/m2 for ∗1∗1 genotype
Number of subjects: 26
Study 29273261 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at 65 mg/m2 for ∗1∗28 genotype
Number of subjects: 26
Study 29273261 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at 80 mg/m2 and 65 mg/m2
Number of subjects: 26
Study 29273261 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine at 625 mg/m2
Number of subjects: 26
Study 29273261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 26
Study 29273261 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 to 4 toxicities
Number of subjects: 26
Study 26630417 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 135
Study 26630417 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (CV)
Number of subjects: 135
Study 24644195 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational interventions (one-to-one and group format)
Number of subjects: 0
Study 24644195 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational interventions
Number of subjects: 0
Study 22554171 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS(12)
Number of subjects: 742
Study 22554171 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS(16)
Number of subjects: 742
Study 22554171 — intervention group
Group type: COMPARATOR
Intervention: LNG-IUS(20)
Number of subjects: 742
Study 20427496 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC126‐0083
Number of subjects: 56
Study 20427496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18062345 — intervention group
Group type: EXPERIMENTAL
Intervention: TAMMEF (Therapeutic Application of a Musically Modulated Electromagnetic Field)
Number of subjects: 60
Study 18062345 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF (Extremely Low Frequencies electromagnetic fields)
Number of subjects: 60
Study 18062345 — intervention group
Group type: COMPARATOR
Intervention: Simulated field
Number of subjects: 60
Study 15596958 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt-table tests
Number of subjects: 0
Study 11962228 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led nutrition education intervention
Number of subjects: 1000
Study 10528662 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysate
Number of subjects: 26
Study 10528662 — intervention group
Group type: COMPARATOR
Intervention: Lactate dialysate
Number of subjects: 26
Study 7738459 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm enrollment for desperate volunteers
Number of subjects: 0
Study 7738459 — intervention group
Group type: COMPARATOR
Intervention: Randomized control for less desperate patients
Number of subjects: 0
Study 1702012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg tds orally)
Number of subjects: 82
Study 1702012 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg tds orally)
Number of subjects: 82
Study 347876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol (14-23 mg/day during acute treatment, average maintenance dose approximately 8 mg, total doses from 3-39 mg for up to four months)
Number of subjects: 30
Study 347876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol (acute treatment)
Number of subjects: 30
Study 31713282 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread or rusks
Number of subjects: 1728
Study 31713282 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate milk
Number of subjects: 1728
Study 31713282 — intervention group
Group type: COMPARATOR
Intervention: Frequency of breakfast consumption
Number of subjects: 1728
Study 31162597 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain pasta enriched with barley β-glucans and Bacillus coagulans BC30, 6086 (INN)
Number of subjects: 41
Study 31162597 — intervention group
Group type: COMPARATOR
Intervention: Whole-grain control pasta (CTR)
Number of subjects: 41
Study 31162597 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain pasta enriched with barley β-glucans and Bacillus coagulans BC30, 6086 (INN) in obese subgroup
Number of subjects: 41
Study 31162597 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain pasta enriched with barley β-glucans and Bacillus coagulans BC30, 6086 (INN) in hyperglycemic subgroup
Number of subjects: 41
Study 28454796 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR) with continuous electrocardiographic monitoring
Number of subjects: 6000
Study 28454796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ILR)
Number of subjects: 6000
Study 25844995 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 169
Study 25844995 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 169
Study 23719048 — intervention group
Group type: EXPERIMENTAL
Intervention: active tDCS+CT
Number of subjects: 60
Study 23719048 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS+CT
Number of subjects: 60
Study 23719048 — intervention group
Group type: COMPARATOR
Intervention: tDCS-only
Number of subjects: 60
Study 21585059 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiguan (SJ 5) group
Number of subjects: 18
Study 21585059 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-acupoint group
Number of subjects: 18
Study 21585059 — intervention group
Group type: COMPARATOR
Intervention: Control group (NASF)
Number of subjects: 18
Study 20051095 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg EGF
Number of subjects: 149
Study 20051095 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg EGF
Number of subjects: 149
Study 20051095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 16455426 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose anthracycline (doxorubicin 50-125 mg/m2)
Number of subjects: 23
Study 15372177 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete prone position (CPP, 180 degrees)
Number of subjects: 59
Study 15372177 — intervention group
Group type: COMPARATOR
Intervention: Incomplete prone position (IPP, 135 degrees)
Number of subjects: 59
Study 11505129 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid fat infusion (0.4 x resting energy expenditure over 6 hrs)
Number of subjects: 18
Study 11505129 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow fat infusion (0.4 x resting energy expenditure over 24 hrs)
Number of subjects: 18
Study 9250846 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (low-molecular-weight heparin) 1 mg/kg body weight, subcutaneously twice daily for 48 hours to 8 days
Number of subjects: 3171
Study 9250846 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin, continuous intravenous administration for 48 hours to 8 days
Number of subjects: 3171
Study 9250846 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (low-molecular-weight heparin)
Number of subjects: 3171
Study 9250846 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3171
Study 7685749 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy followed by high-dose (40 Gy) total or subtotal nodal irradiation
Number of subjects: 70
Study 7685749 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP/ABVD chemotherapy followed by high-dose (40 Gy) total or subtotal nodal irradiation
Number of subjects: 70
Study 3494461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (24 mg/kg/day) for 4 days
Number of subjects: 33
Study 3494461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 33
Study 31888928 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC-based treatment strategy
Number of subjects: 0
Study 31888928 — intervention group
Group type: COMPARATOR
Intervention: INR-guided VKA-management
Number of subjects: 0
Study 28682187 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message emphasizing consequence of not receiving flu vaccine
Number of subjects: 163
Study 28682187 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed message emphasizing consequence of receiving flu vaccine
Number of subjects: 163
Study 26138866 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg retosiban
Number of subjects: 52
Study 26138866 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg retosiban
Number of subjects: 52
Study 26138866 — intervention group
Group type: COMPARATOR
Intervention: 400 mg moxifloxacin (positive control)
Number of subjects: 52
Study 26138866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26138866 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratherapeutic exposure of retosiban
Number of subjects: 52
Study 26138866 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exposure of retosiban
Number of subjects: 52
Study 23828160 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/Reboxetine (4 mg BID)
Number of subjects: 54
Study 23828160 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine/Placebo
Number of subjects: 54
Study 21976525 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent group (always reinforced with a specific reward outcome)
Number of subjects: 0
Study 21976525 — intervention group
Group type: COMPARATOR
Intervention: Inconsistent group (reinforced with randomly selected rewards)
Number of subjects: 0
Study 21976525 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC activity
Number of subjects: 0